{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:14:52Z","timestamp":1789352092457,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T00:00:00Z","timestamp":1215475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Genotypic interpretation systems extrapolate observed associations in datasets to predict viral susceptibility to antiretroviral drugs (ARVs) for given isolates. We aimed to develop and validate an approach using artificial neural networks (ANNs) that employ descriptors of physiochemical properties for mutations in HIV\u20101 protease (PR) and reverse transcriptase (RT) to predict phenotypic susceptibility to all currently approved ARVs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We extracted pairs of PR and RT gene sequences (<jats:italic>n<\/jats:italic>=1507; 98.5% sub\u2010type B) and their corresponding exact phenotype values (PhenoSense only, <jats:italic>n<\/jats:italic>=10\u2003132) from the Stanford HIV database. All amino acid positions and mixture codes were accounted for. For each ARV, an ANN was trained with 10\u2010fold internal cross\u2010validation. The predictive abilities of these trained ANNs were validated on separate datasets.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Correlation coefficients between observed and predicted phenotype values in the 10\u2010fold cross\u2010validation ranged from: 0.75 (tenofovir) to 0.94 [lamivudine (3TC)] for nucleoside RT inhibitors (NRTIs); 0.82 [efavirenz (EFV)] to 0.83 [nevirapine (NVP)] for non\u2010nucleoside RT inhibitors (NNRTIs); and 0.83 (atazanavir) to 0.92 (ritonavir) for PR inhibitors (PIs). For the validation set the correlation coefficients ranged from 0.76 (didanosine) to 0.96 (3TC) for NRTIs; 0.68 (EFV) to 0.81 (NVP) for NNRTIs; and 0.88 (amprenavir) to 0.95 (saquinavir) for PIs. For C sub\u2010type predictions, with ANNs trained on sub\u2010type B data, the correlation coefficient was 0.89.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ANNs, based on the physiochemical properties of the PR and RT amino\u2010acid sequences, predict phenotypic susceptibility to ARVs inhibiting these enzymes to an extent that is comparable to routine phenotypic susceptibility testing. These ANNs can also be used to predict resistance to C sub\u2010types.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2008.00612.x","type":"journal-article","created":{"date-parts":[[2008,7,9]],"date-time":"2008-07-09T05:14:24Z","timestamp":1215580464000},"page":"642-652","source":"Crossref","is-referenced-by-count":12,"title":["Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks"],"prefix":"10.1111","volume":"9","author":[{"given":"J","family":"Kj\u00e6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"H\u00f8j","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JD","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,9,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1097\/00002030-200006160-00001","article-title":"A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS","volume":"16","author":"Baxter JD","year":"2000","journal-title":"AIDS"},{"key":"e_1_2_6_3_2","first-page":"369","article-title":"Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy","volume":"16","author":"Cingolani A","year":"2002","journal-title":"a randomized study (ARGENTA)"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203080-00009"},{"key":"e_1_2_6_5_2","first-page":"2195","article-title":"Drug\u2010resistance genotyping in HIV\u20101 therapy","volume":"353","author":"Durant J","year":"1999","journal-title":"the VIRADAPT Randomised Controlled Trial"},{"key":"e_1_2_6_6_2","first-page":"727","article-title":"Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure","volume":"16","author":"Meynard JL","year":"2002","journal-title":"a randomized trial"},{"key":"e_1_2_6_7_2","first-page":"209","article-title":"Clinical utility of HIV\u20101 genotyping and expert advice","volume":"16","author":"Tural C","year":"2002","journal-title":"the Havana Trial"},{"key":"e_1_2_6_8_2","unstructured":"Been\u2010TiktakA KornK KeulenWet al. Evaluation of an open expert\u2010based genotype interpretation program: RetroGram.41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago IL December 2001 [Abstract I\u20101745]."},{"key":"e_1_2_6_9_2","unstructured":"Agence Nationale de Recherches sur le SIDA (ANRS).ANRS Genotypic Resistance Guidelines \u2013 version 13.http:\/\/www.hivfrenchresistance.org\/2005."},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1177\/135965350400900406","article-title":"Construction, training and clinical validation of an interpretation system for genotypic HIV\u20101 drug resistance based on fuzzy rules revised by virological outcomes","volume":"9","author":"De Luca A","year":"2004","journal-title":"Antivir Ther"},{"key":"e_1_2_6_11_2","first-page":"256","article-title":"An updated guide to genotype interpretation","volume":"14","author":"MacArthur RD.","year":"2004","journal-title":"AIDS Reader"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00244.x"},{"key":"e_1_2_6_13_2","unstructured":"Retrovirology Laboratory Luxembourg.Centre Hospitalier Luxembourg.http:\/\/www.ablsa.com\/site\/en\/product_vs.html2003."},{"key":"e_1_2_6_14_2","unstructured":"ShaferRW RheeSY ZioniRet al.HIV Drug Resistance Database.http:\/\/hivdb.stanford.edu\/pages\/asi\/releaseNotes\/2006."},{"key":"e_1_2_6_15_2","unstructured":"VercauterenJ Van LaethemK DeforcheK CamachoR VandammeA.REGA genotypic resistance interpretation system \u2013 version 6.4.http:\/\/www.kuleuven.ac.be\/rega\/cev\/links\/rega_algorithm\/index.htm2004."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/135965350400900619"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200312000-00010"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2003.00131.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/135965350300800308","article-title":"Comparison of nine resistance interpretation systems for HIV\u20101 genotyping","volume":"8","author":"Sturmer M","year":"2003","journal-title":"Antivir Ther"},{"key":"e_1_2_6_20_2","first-page":"S102","article-title":"Predictive value of different drug resistance interpretation systems in therapy management of HIV\u2010infected patients in daily routine","volume":"7","author":"Braun P","year":"2002","journal-title":"Antivir Ther"},{"key":"e_1_2_6_21_2","first-page":"787","article-title":"Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir","volume":"9","author":"Cabrera C","year":"2004","journal-title":"EuroSIDA Study"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/03008870310009623","article-title":"Interpretation systems for genotypic drug resistance of HIV\u20101","volume":"106","author":"De Luca A","year":"2003","journal-title":"Scand J Infect Dis Suppl"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.694-701.2006"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00002"},{"issue":"3","key":"e_1_2_6_25_2","article-title":"Quantitative prediction of HIV\u20101 phenotypic drug resistance from genotypes","volume":"5","author":"Larder BA","year":"2000","journal-title":"the virtual phenotype (VirtualPhenotype)"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607274103"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000147526.64863.53"},{"key":"e_1_2_6_28_2","first-page":"368","article-title":"AAindex","volume":"27","author":"Kawashima S","year":"1999","journal-title":"amino acid index database"},{"key":"e_1_2_6_29_2","unstructured":"N\u00f8rgaardM.Neural network based system identification toolbox. [Report no.: tech. report 00\u2010E\u2010891]. Lyngby: Department of Automation Technical University of Denmark 2000."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/377453"},{"key":"e_1_2_6_31_2","first-page":"3850","article-title":"Geno2pheno","volume":"31","author":"Beerenwinkel N","year":"2003","journal-title":"estimating phenotypic drug resistance from HIV-1 genotypes"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2008.00612.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2008.00612.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T21:24:31Z","timestamp":1696886671000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2008.00612.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1468-1293.2008.00612.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00612.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}